6533b820fe1ef96bd127a582

RESEARCH PRODUCT

HepaDisk – A new quality of life questionnaire for HCV patients

Stefano FagiuoliNicola CaporasoFilomena MoriscoFabio BuelliGiuliana GualbertiValeria SaragagliaLuchino ChessaGiampaolo CortiIvana MaidaClaudio M. MastroianniMario PirisiFrancesco P. RussoFrancesca FarinaLydia GiannitrapaniPierluigi ToniuttoPierluigi TarquiniPaolo TundoJacopo VecchietMaria VinciGloria Taliani Hepadisk Study Group

subject

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaPsychometricsgastroenterologyDiseaseSeverity of Illness IndexCorrelation03 medical and health sciencesLiver disease0302 clinical medicineQuality of lifeDisease severityCronbach's alphaSurveys and QuestionnairesInternal medicinemedicineHumansAgedRank correlationAged 80 and overbusiness.industryBurden of diseaseReproducibility of Resultspsychometric validationMiddle Agedmedicine.diseaseHepatitis CPsychometric validationburden of disease; hcv; pro development; psychometric validation; hepatology; gastroenterologyItaly030220 oncology & carcinogenesishepatologyHCVPRO developmentQuality of LifeFemale030211 gastroenterology & hepatologyObservational studybusiness

description

Abstract Background Since most patients with hepatitis C virus (HCV) infection now receive treatment irrespective of liver disease severity, special attention to patient quality of life (QoL), including psycho-social aspects, is required. No QoL questionnaire is specific for patients with HCV. Aims To develop and validate a short Italian questionnaire (HepaDisk) assessing the QoL of patients affected by HCV with intuitive graphic results that is understandable by patients and physicians. Methods A questionnaire, drafted by a steering committee, underwent a Delphi survey. A multicenter, observational study was conducted to validate the developed HepaDisk versus other tools (CLDQ-I, SF-36, WPAI:HCV), and to evaluate its correlation with disease severity in Italian patients with HCV. Results The 10-item questionnaire was validated in 214 patients. HepaDisk showed a high correlation with CLDQ overall score and WPAI:HCV activity impairment (Spearman’s rank correlation: 0.651 and 0.595, respectively) and a lower correlation with SF-36. Strong internal consistency (Cronbach coefficient: 0.912), good test–retest reliability (Pearson’s correlation coefficient: 0.789; 95% CI, 0.714–0.865), and responsiveness to changes among improved patients were demonstrated. Conclusion HepaDisk is a reliable and user-friendly tool that can monitor disease impact on patient QoL over time, providing a visual representation easily understandable by both patients and physicians.

yearjournalcountryeditionlanguage
2019-07-01
10.1016/j.dld.2018.12.009http://hdl.handle.net/10281/354047